Literature DB >> 20024165

Fluence rate-dependent intratumor heterogeneity in physiologic and cytotoxic responses to Photofrin photodynamic therapy.

Theresa M Busch1, Xiaoman Xing, Guoqiang Yu, Arjun Yodh, E Paul Wileyto, Hsing-Wen Wang, Turgut Durduran, Timothy C Zhu, Ken Kang-Hsin Wang.   

Abstract

Photodynamic therapy (PDT) can lead to the creation of heterogeneous, response-limiting hypoxia during illumination, which may be controlled in part through illumination fluence rate. In the present report we consider (1) regional differences in hypoxia, vascular response, and cell kill as a function of tumor depth and (2) the role of fluence rate as a mediator of depth-dependent regional intratumor heterogeneity. Intradermal RIF murine tumors were treated with Photofrin PDT using surface illumination at an irradiance of 75 or 38 mW cm(-2). Regional heterogeneity in tumor response was examined through comparison of effects in the surface vs. base of tumors, i.e. along a plane parallel to the skin surface and perpendicular to the incident illumination. 75 mW cm(-2) PDT created significantly greater hypoxia in tumor bases relative to their surfaces. Increased hypoxia in the tumor base could not be attributed to regional differences in Photofrin concentration nor effects of fluence rate distribution on photochemical oxygen consumption, but significant depth-dependent heterogeneity in vascular responses and cytotoxic response were detected. At a lower fluence rate of 38 mW cm(-2), no detectable regional differences in hypoxia or cytotoxic responses were apparent, and heterogeneity in vascular response was significantly less than that during 75 mW cm(-2) PDT. This research suggests that the benefits of low-fluence-rate PDT are mediated in part by a reduction in intratumor heterogeneity in hypoxic, vascular and cytotoxic responses.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20024165      PMCID: PMC2834171          DOI: 10.1039/b9pp00004f

Source DB:  PubMed          Journal:  Photochem Photobiol Sci        ISSN: 1474-905X            Impact factor:   3.982


  33 in total

1.  Noninvasive monitoring of murine tumor blood flow during and after photodynamic therapy provides early assessment of therapeutic efficacy.

Authors:  Guoqiang Yu; Turgut Durduran; Chao Zhou; Hsing-Wen Wang; Mary E Putt; H Mark Saunders; Chandra M Sehgal; Eli Glatstein; Arjun G Yodh; Theresa M Busch
Journal:  Clin Cancer Res       Date:  2005-05-01       Impact factor: 12.531

2.  Choice of optimal wavelength for PDT: the significance of oxygen depletion.

Authors:  Kristian P Nielsen; Asta Juzeniene; Petras Juzenas; Knut Stamnes; Jakob J Stamnes; Johan Moan
Journal:  Photochem Photobiol       Date:  2005 Sep-Oct       Impact factor: 3.421

3.  The effect of fluence rate on tumor and normal tissue responses to photodynamic therapy.

Authors:  T M Sitnik; B W Henderson
Journal:  Photochem Photobiol       Date:  1998-04       Impact factor: 3.421

4.  Tumor vascular response to photodynamic therapy and the antivascular agent 5,6-dimethylxanthenone-4-acetic acid: implications for combination therapy.

Authors:  Mukund Seshadri; Joseph A Spernyak; Richard Mazurchuk; Susan H Camacho; Allan R Oseroff; Richard T Cheney; David A Bellnier
Journal:  Clin Cancer Res       Date:  2005-06-01       Impact factor: 12.531

5.  Broadband reflectance measurements of light penetration, blood oxygenation, hemoglobin concentration, and drug concentration in human intraperitoneal tissues before and after photodynamic therapy.

Authors:  Hsing-Wen Wang; Timothy C Zhu; Mary E Putt; Michael Solonenko; James Metz; Andreea Dimofte; Jeremy Miles; Douglas L Fraker; Eli Glatstein; Stephen M Hahn; Arjun G Yodh
Journal:  J Biomed Opt       Date:  2005 Jan-Feb       Impact factor: 3.170

6.  Photodynamic therapy of actinic keratosis at varying fluence rates: assessment of photobleaching, pain and primary clinical outcome.

Authors:  M B Ericson; C Sandberg; B Stenquist; F Gudmundson; M Karlsson; A-M Ros; A Rosén; O Larkö; A-M Wennberg; I Rosdahl
Journal:  Br J Dermatol       Date:  2004-12       Impact factor: 9.302

7.  Treatment-induced changes in tumor oxygenation predict photodynamic therapy outcome.

Authors:  Hsing-Wen Wang; Mary E Putt; Michael J Emanuele; Daniel B Shin; Eli Glatstein; Arjun G Yodh; Theresa M Busch
Journal:  Cancer Res       Date:  2004-10-15       Impact factor: 12.701

8.  Combining vascular and cellular targeting regimens enhances the efficacy of photodynamic therapy.

Authors:  Bin Chen; Brian W Pogue; P Jack Hoopes; Tayyaba Hasan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-03-15       Impact factor: 7.038

9.  Hypoxia and Photofrin uptake in the intraperitoneal carcinomatosis and sarcomatosis of photodynamic therapy patients.

Authors:  Theresa M Busch; Stephen M Hahn; E Paul Wileyto; Cameron J Koch; Douglas L Fraker; Paul Zhang; Mary Putt; Kristen Gleason; Daniel B Shin; Michael J Emanuele; Kevin Jenkins; Eli Glatstein; Sydney M Evans
Journal:  Clin Cancer Res       Date:  2004-07-15       Impact factor: 12.531

10.  Reduction of tumour oxygenation during and after photodynamic therapy in vivo: effects of fluence rate.

Authors:  T M Sitnik; J A Hampton; B W Henderson
Journal:  Br J Cancer       Date:  1998-05       Impact factor: 7.640

View more
  31 in total

1.  Tumor vascular microenvironment determines responsiveness to photodynamic therapy.

Authors:  Amanda L Maas; Shirron L Carter; E Paul Wileyto; Joann Miller; Min Yuan; Guoqiang Yu; Amy C Durham; Theresa M Busch
Journal:  Cancer Res       Date:  2012-02-28       Impact factor: 12.701

2.  Increasing damage to tumor blood vessels during motexafin lutetium-PDT through use of low fluence rate.

Authors:  Theresa M Busch; Hsing-Wen Wang; E Paul Wileyto; Guoqiang Yu; Ralph M Bunte
Journal:  Radiat Res       Date:  2010-09       Impact factor: 2.841

3.  A Comparison of Dose Metrics to Predict Local Tumor Control for Photofrin-mediated Photodynamic Therapy.

Authors:  Haixia Qiu; Michele M Kim; Rozhin Penjweini; Jarod C Finlay; Theresa M Busch; Tianhao Wang; Wensheng Guo; Keith A Cengel; Charles B Simone; Eli Glatstein; Timothy C Zhu
Journal:  Photochem Photobiol       Date:  2017-02-22       Impact factor: 3.421

Review 4.  Photodynamic therapy in the management of pre-malignant head and neck mucosal dysplasia and microinvasive carcinoma.

Authors:  Harry Quon; Craig E Grossman; Jarod C Finlay; Timothy C Zhu; Clarice S Clemmens; Kelly M Malloy; Theresa M Busch
Journal:  Photodiagnosis Photodyn Ther       Date:  2011-06       Impact factor: 3.631

5.  A fluorescent nanoprobe for real-time monitoring of intracellular singlet oxygen during photodynamic therapy.

Authors:  Jian-Tao Ping; Hong-Shang Peng; Jinglei Qin; Fang-Tian You; Yi-Quan Wang; Gen-Xiang Chen; Min Song
Journal:  Mikrochim Acta       Date:  2018-04-26       Impact factor: 5.833

6.  Photodynamic therapy-induced angiogenic signaling: consequences and solutions to improve therapeutic response.

Authors:  Shannon M Gallagher-Colombo; Amanda L Maas; Min Yuan; Theresa M Busch
Journal:  Isr J Chem       Date:  2012-09-01       Impact factor: 3.333

7.  Anticancer drug released from near IR-activated prodrug overcomes spatiotemporal limits of singlet oxygen.

Authors:  Pallavi Rajaputra; Moses Bio; Gregory Nkepang; Pritam Thapa; Sukyung Woo; Youngjae You
Journal:  Bioorg Med Chem       Date:  2016-02-21       Impact factor: 3.641

Review 8.  Preoperative mapping of nonmelanoma skin cancer using spatial frequency domain and ultrasound imaging.

Authors:  Daniel J Rohrbach; Daniel Muffoletto; Jonathan Huihui; Rolf Saager; Kenneth Keymel; Anne Paquette; Janet Morgan; Nathalie Zeitouni; Ulas Sunar
Journal:  Acad Radiol       Date:  2014-02       Impact factor: 3.173

9.  A light emitting diode (LED) based spatial frequency domain imaging system for optimization of photodynamic therapy of nonmelanoma skin cancer: quantitative reflectance imaging.

Authors:  R B Saager; D J Cuccia; S Saggese; K M Kelly; A J Durkin
Journal:  Lasers Surg Med       Date:  2013-04       Impact factor: 4.025

10.  Lesion oxygenation associates with clinical outcomes in premalignant and early stage head and neck tumors treated on a phase 1 trial of photodynamic therapy.

Authors:  Peter H Ahn; Jarod C Finlay; Shannon M Gallagher-Colombo; Harry Quon; Bert W O'Malley; Gregory S Weinstein; Ara Chalian; Kelly Malloy; Thomas Sollecito; Martin Greenberg; Charles B Simone; Sally McNulty; Alexander Lin; Timothy C Zhu; Virginia Livolsi; Michael Feldman; Rosemarie Mick; Keith A Cengel; Theresa M Busch
Journal:  Photodiagnosis Photodyn Ther       Date:  2017-11-04       Impact factor: 3.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.